Analysts Set Expectations for Haemonetics FY2027 Earnings

Haemonetics Co. (NYSE:HAE) – Research analysts at Zacks Research decreased their FY2027 earnings per share (EPS) estimates for shares of Haemonetics in a report issued on Monday, February 3rd. Zacks Research analyst R. Department now expects that the medical instruments supplier will post earnings of $5.90 per share for the year, down from their previous estimate of $5.91. The consensus estimate for Haemonetics’ current full-year earnings is $4.59 per share.

HAE has been the subject of several other research reports. Raymond James upgraded Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 price target for the company in a research note on Friday, November 8th. JPMorgan Chase & Co. began coverage on Haemonetics in a research report on Friday, December 6th. They set an “overweight” rating and a $116.00 target price for the company. Barrington Research restated an “outperform” rating and issued a $108.00 price objective on shares of Haemonetics in a research note on Wednesday, December 4th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $112.00 price objective on shares of Haemonetics in a report on Tuesday, December 3rd. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $108.78.

Haemonetics Trading Up 4.4 %

Shares of NYSE:HAE opened at $69.03 on Wednesday. Haemonetics has a 1 year low of $65.73 and a 1 year high of $97.97. The firm has a fifty day moving average price of $78.16 and a 200 day moving average price of $78.93. The company has a current ratio of 3.49, a quick ratio of 2.09 and a debt-to-equity ratio of 1.39. The stock has a market capitalization of $3.47 billion, a PE ratio of 28.64, a P/E/G ratio of 1.07 and a beta of 0.39.

Haemonetics (NYSE:HAE) last posted its earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.09 by $0.03. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. The firm had revenue of $345.50 million during the quarter, compared to analysts’ expectations of $342.57 million. During the same period in the previous year, the company earned $0.99 earnings per share. The company’s revenue was up 8.6% compared to the same quarter last year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Nisa Investment Advisors LLC grew its position in Haemonetics by 124.2% during the third quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier’s stock worth $92,000 after buying an additional 632 shares in the last quarter. KBC Group NV lifted its position in shares of Haemonetics by 54.6% in the 4th quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier’s stock worth $157,000 after acquiring an additional 712 shares during the period. iSAM Funds UK Ltd acquired a new stake in shares of Haemonetics during the 3rd quarter worth approximately $204,000. CWC Advisors LLC. bought a new stake in shares of Haemonetics during the third quarter valued at approximately $231,000. Finally, Versor Investments LP raised its stake in shares of Haemonetics by 9.1% in the third quarter. Versor Investments LP now owns 3,600 shares of the medical instruments supplier’s stock valued at $289,000 after purchasing an additional 300 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.